Andrew Hantel, MD
Enriched profileAssistant Professor of Medicine, Harvard Medical School · Dana-Farber Cancer Institute
Andrew Hantel is Assistant Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute. OpenAlex indexes 111 publications with 1,780 citations (h-index 19); ClinicalTrials.gov lists 4 registered studies with this person as an investigator.
Data verified 25 Oct 2026
Overview
Updated 2 Nov 2026
Andrew Hantel, M.D., is Assistant Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute. The public record shows 111 publications with 1,780 citations (h-index 19), centered on Ethics in Clinical Research, Acute Myeloid Leukemia Research, Statistical Methods in Clinical Trials. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 7 companies, 1 NIH-funded awards (2022–2026).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Ethics in Clinical Research
- 4 registered trials on ClinicalTrials.gov
- Open Payments reporting from 7 companies
Generated from the cited public record · current as of 2 Nov 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 22 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 33.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 2 Nov 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Sponsor: Andrew Hantel, MD
- Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
Sponsor: Dana-Farber Cancer Institute
- Pilot of a Trial Enrollment Diversity Dashboard
Sponsor: Dana-Farber Cancer Institute
Industry payments
Updated 2 Nov 2026
7 companies reported payments to CMS in program years 2023–2025. These are public disclosures, not judgments. The latest:
- JAZZ PHARMACEUTICALS INC.Program year20251 payment
- Genentech, Inc.Program year20241 payment$10,000openpaymentsdata.cms.gov ↗
- JAZZ PHARMACEUTICALS INC.Program year20241 payment
NIH funding
Updated 2 Nov 2026
1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:
- Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention
Dana-Farber Cancer Inst
FY2026$207,900K08CA273043 - Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention
Dana-Farber Cancer Inst
FY2025$255,716K08CA273043 - Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention
Dana-Farber Cancer Inst
FY2024$254,592K08CA273043
Congress activity
Updated 2 Nov 2026
31 congress contributions (2015–2026) across ASCO, ASH per OpenAlex. The most recent:
- When disaster strikes: A scoping review of climate-resilience toolkits relevant to cancer care delivery.
ASCO Annual Meeting
ASCO2026Co-author - Association between extreme heat exposures and survival in patients with multiple myeloma
ASH Annual Meeting
ASH2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 2 Nov 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Ethical Design and Implementation of Monetary Transfer Interventions in Clinical Cancer Research.
Journal of clinical oncology
Article2026 - The Duffy antigen: A narrative review of testing, epidemiology, neutrophil counts and clinical consequences.
British journal of haematology
Review2025
Most-cited works
by citation count (OpenAlex)- 01TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic SyndromesArticle795 citations2016
- 02
- 03Validation of a financial toxicity (FT) grading system.Conference abstract69 citations2017
- 04
- 05
Network
Updated 2 Nov 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 2 Nov 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/andrew-hantel-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
bioethics.hms.harvard.edu/faculty-staff/andrew-hantel
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bioethics.hms.harvard.edu ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 2 Nov 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Loyola University Chicago
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - MPH
Harvard School of Public Health
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bioethics.hms.harvard.edu ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →connects.catalyst.harvard.edu ↗
- Research funding and award
Leukemia and Lymphoma Society (program not identified)
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bioethics.hms.harvard.edu ↗
Secondary affiliations
appointments beyond the home institution- Member
HMS Center for Bioethics
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bioethics.hms.harvard.edu ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ajmc.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →powerfulpatients.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Frank Hodi, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center